{"entity":{"id":"nct02180724","kind":"trial","name":"An Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström Macroglobulinemia","aka":[],"tldr":"A phase 2 trial of Acalabrutinib in waldenström macroglobulinaemia, run by Acerta Pharma BV, active and no longer recruiting.","summary":"An Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström Macroglobulinemia is a phase 2 interventional study registered as NCT02180724 by Acerta Pharma BV, with 107 participants enrolled, started 2014-09-11 and due to reach its primary completion in 2019-10-01. Interventions recorded: Acalabrutinib (ACP-196). Results have been posted on the registry.","status":"active","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT02180724","url":"https://clinicaltrials.gov/study/NCT02180724"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["waldenstrom"],"sections":[],"technologies":["kinase-inhibitors"],"targets":[],"drugs":["acalabrutinib"],"companies":["astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT02180724","phase":"2","setting":"An Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström Macroglobulinemia","sponsor":"Acerta Pharma BV","started":"2014-09-11","startedType":"actual","yearReported":2020,"enrolled":107,"enrolledBasis":"registry","outcomes":[{"endpoint":"Overall Response Rate (ORR) of Acalabrutinib in Subjects as Assessed by Investigator Per IWWM 6th Criteria, ORR 6th IWWM criteria (CR+VGPR+PR+MR)","primary":true,"unit":"participants","arms":[{"name":"Previously Treated (N=92)","n":92,"value":87,"note":"Figures from the ClinicalTrials.gov results section (first posted 2020-04-24), not from a publication"},{"name":"Treatment Naive (N=14)","n":14,"value":13}],"source":"https://clinicaltrials.gov/study/NCT02180724?tab=results"},{"endpoint":"Overall Response Rate (ORR) of Acalabrutinib in Subjects as Assessed by Investigator Per IWWM 3rd Criteria, ORR 3rd IWWM criteria (CR+VGPR+PR+MR)","primary":true,"unit":"participants","arms":[{"name":"Previously Treated (N=92)","n":92,"value":87,"note":"Figures from the ClinicalTrials.gov results section (first posted 2020-04-24), not from a publication"},{"name":"Treatment Naive (N=14)","n":14,"value":13}],"source":"https://clinicaltrials.gov/study/NCT02180724?tab=results"}]},"route":"/trials/nct02180724/","neighbours":{"cancer":[{"id":"waldenstrom","kind":"cancer","name":"Waldenström macroglobulinaemia","route":"/cancers/waldenstrom/"}],"technology":[{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"acalabrutinib","kind":"drug","name":"Acalabrutinib","route":"/drugs/acalabrutinib/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"}]}}